Strong 27% revenue growth, a perfect four-quarter earnings beat streak averaging nearly 25% upside surprise, and a 4-to-1 favorable risk/reward combine to make a compelling long-side case, with the primary watch items being a leverage penalty from a debt-to-equity ratio of 2.5 and a current momentum headwind while the longer-term trend remains intact.
Thesis pillars
- Strong Growth Best In Class Margins↓Deteriorating
- Perfect Earnings Beat Streak→Stable
- Favorable Analyst Risk Reward→Stable
- +1 more pillar — see the Why tab for full reasoning
Globus Medical, Inc. (GMED) Stock Analysis
Healthcare · Medical Devices
Wait for pullback to $73.70. Below 200-day MA (death cross); also weak momentum, recent C-suite change — blocks BUY_NOW at $74.52. Engine's entry $73.70 (support + ATR) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Below 200-day MA.
Globus Medical designs and sells musculoskeletal implants, biologics, spinal cord stimulation systems, and robotic surgical navigation platforms to hospitals and surgery centers. Products are distributed through an exclusive direct and distributor salesforce across 65 countries,... Read more
Wait for pullback to $73.70. Below 200-day MA (death cross); also weak momentum, recent C-suite change — blocks BUY_NOW at $74.52. Engine's entry $73.70 (support + ATR) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Below 200-day MA. Chart setup: No clear chart pattern; technical signals are mixed. Strong overall profile with balanced scores. Score 6.8/10, high confidence.
Passes 7/10 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 41d clear, semi cycle peak clear, materials cycle peak clear). Fails on death cross (50MA < 200MA). Suitability: moderate.
About Globus Medical, Inc.
About Globus Medical, Inc.
Globus Medical launched 9 new products in 2025, including the Excelsius XR wearable extended reality navigation headset, and completed the acquisition of Nevro on April 3, 2025, adding the HFX spinal cord stimulation platform for chronic pain treatment. International sales represented approximately 19.4% of total 2025 revenue, with the remainder generated in the United States. The company maintained a direct or distributor sales presence in 65 countries as of December 31, 2025.
The company earns revenue through device sales across two categories: Musculoskeletal Solutions—spanning spinal implants, orthopedic trauma products, arthroplasty systems, spinal cord stimulation, and neuromonitoring services—and Enabling Technologies, which includes the ExcelsiusGPS robotic guidance platform, the Excelsius3D intraoperative imaging system, and the ExcelsiusXR extended reality headset. Products are sold through an exclusive direct sales force and independent distributor networks; sales representatives are typically present in the operating room during U.S. surgeries. Key competitors include Medtronic, DePuy Synthes, Stryker, Zimmer Biomet, and Smith + Nephew, all with substantially greater financial resources. Manufacturing occurs at facilities in Pennsylvania, Ohio, Texas, Massachusetts, and Costa Rica, with a number of products outsourced to third-party suppliers.
Show full overview
The supplier dependency the 10-K identifies is notable: the company relies on a limited number of third-party manufacturers for components and finished products, and cannot quickly substitute replacement suppliers for many critical components due to FDA regulatory requirements, custom-part specifications, and ISO-13485 certification constraints. Allograft tissue for the Osteocel Plus and Osteocel Pro biologic lines is sourced from several tissue banks with no easily substitutable manufacturing pathway. Disruptions to this limited supply base from equipment failure, quality non-compliance, or geopolitical events may impact product availability and revenue.
See also: Healthcare · Medical Devices
From Globus Medical, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-09-26Recent Developments — Globus Medical, Inc.
Latest news
- NEWS GMED Q1 2026 Earnings: Robust EPS Surprise Offsets Minor Stock Decline - Pre-Earnings Setup - dars.gov.et — dars.gov.et positive
- NEWS Globus Medical (GMED) Stock Could Be Undervalued Following Q2 Earnings Date - simplywall.st — simplywall.st positive
- NEWS Globus Medical (GMED) Stock: Technical Signals Overview | Q4 2025: Better Than Expected - Acquisition - Newser — Newser positive
- NEWS Globus Medical (GMED) Stock: Technical Signals Overview | Q4 2025: Better Than Expected - Crowd Breakout Signals - Newse — Newser positive
- NEWS Earnings Beat Amid Currency Headwinds Might Change The Case For Investing In Globus Medical (GMED) - Sahm — Sahm positive
Generated 2026-09-26T13:06:57Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- LOWGeographicinternational sales19%10-K Item 1: 'international sales accounted for approximately 19.4% of our total sales'
- MEDIUMSupplierlimited number of third-party suppliers10-K Item 1A: 'We are dependent on a limited number of third-party suppliers, and the loss of any of these suppliers ... could harm our business'
Material Events(8-K, last 90d)
- 2026-06-04Item 5.02LOWStockholders approved amendment to 2021 Equity Incentive Plan on June 3, 2026, increasing authorized shares by 1,000,000 to 12,000,000 total. Compensatory arrangement approval; no officer departure.SEC filing →
- 2026-03-23Item 5.02LOWDirector John A. DeFord, Ph.D. resigned from the Board effective March 23, 2026. No disagreement with the Company cited. No successor named.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $73.70. Below 200-day MA (death cross); also weak momentum, recent C-suite change — blocks BUY_NOW at $74.52. Engine's entry $73.70 (support + ATR) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Below 200-day MA. Chart setup: No clear chart pattern; technical signals are mixed. Strong overall profile with balanced scores. Target $89.81 (+20.5%), stop $70.65 (−5.5%), A.R:R 4.1:1. Score 6.8/10, high confidence.
Take-profit target: $89.81 (+20.5% upside). Target $89.81 (+20.5%), stop $70.65 (−5.5%), A.R:R 4.1:1. Stop-loss: $70.65.
Below 200-day MA.
Globus Medical, Inc. trades at a P/E of 18.9 (forward 13.8). TrendMatrix value score: 8.0/10. Verdict: Buy (Wait for Entry).
23 analysts cover GMED with a consensus score of 3.9/5. Average price target: $103.
What does Globus Medical, Inc. do?Globus Medical designs and sells musculoskeletal implants, biologics, spinal cord stimulation systems, and robotic...
Globus Medical designs and sells musculoskeletal implants, biologics, spinal cord stimulation systems, and robotic surgical navigation platforms to hospitals and surgery centers. Products are distributed through an exclusive direct and distributor salesforce across 65 countries, with approximately 80.6% of 2025 sales from the United States.